> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Since Our Last Issue ...
- URL: https://www.fdaweb.com/since-our-last-issue-107/
- Published: 2018-03-11T12:00:00.000Z
- Updated: 2026-09-14T23:29:02.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5140956

**Biogen** has agreed to purchase **Pfizer**’s PF-04958242, a first-in-class, Phase 2b-ready drug being evaluating to treat several neurological and psychiatric diseases, including schizophrenia. Biogen is paying $75 million upfront for the compound, and the agreement could include up to $515 million in developmental and commercial milestones.

**Laborie Medical Technologies** has agreed to pay $214 million to acquire **Cogentix Medical**. The transaction would give Laborie to Cogentix Medical’s Urgent PC Neuromodulation System, a non-drug, non-surgical treatment for overactive bladder and associated symptoms of urinary urgency, urinary frequency and urge incontinence.

**Seattle Genetics** has acquired **Cascadian Therapeutics** and its tucatinib, an investigational oral tyrosine kinase inhibitor that is highly selective for HER2, a growth factor receptor overexpressed in multiple cancers, including breast, colorectal, ovarian and gastric. Tucatinib is currently being evaluated in a pivotal trial called HER2CLIMB for patients with HER2-positive metastatic breast cancer, including patients with or without brain metastases.